GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxford BioDynamics PLC (OTCPK:OXBOF) » Definitions » Net Change in Cash

Oxford BioDynamics (Oxford BioDynamics) Net Change in Cash : $5.29 Mil (TTM As of Sep. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Oxford BioDynamics Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Oxford BioDynamics's Net Change in Cash for the six months ended in Sep. 2023 was $5.02 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Sep. 2023 was $5.29 Mil.

Oxford BioDynamics Net Change in Cash Historical Data

The historical data trend for Oxford BioDynamics's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oxford BioDynamics Net Change in Cash Chart

Oxford BioDynamics Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only -16.19 1.19 -5.42 -1.36 5.29

Oxford BioDynamics Semi-Annual Data
Sep13 Sep14 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.86 1.02 -2.24 0.27 5.02

Oxford BioDynamics Net Change in Cash Calculation

Oxford BioDynamics's Net Change in Cash for the fiscal year that ended in Sep. 2023 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-10.265+-0.767+16.345+-0.021
=5.29

Oxford BioDynamics's Net Change in Cash for the quarter that ended in Sep. 2023

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-3.802+2.48+6.337+0
=5.02

Net Change in Cash for the trailing twelve months (TTM) ended in Sep. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $5.29 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oxford BioDynamics Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Oxford BioDynamics's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Oxford BioDynamics (Oxford BioDynamics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxford BioDynamics PLC (OTCPK:OXBOF) » Definitions » Net Change in Cash
Comparable Companies
LSE:4BB LSE:ETX LSE:AREC LSE:REDX LSE:SBTX LSE:DEST LSE:FUM LSE:SAR LSE:TRX LSE:C4XD OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
OBD:UK
Address
Oxford Business Park South, 3140 Rowan Place, John Smith Drive, Oxford, GBR, OX4 2WB
Website
https://www.oxfordbiodynamics.com
Oxford BioDynamics PLC is a biotechnology company. The company focuses on the discovery and development of biomarkers for use within the pharmaceutical and biotechnology industry. It provides a technology platform Episwitch which aims to accelerate the drug discovery and development process and improve the success rate of therapeutic product development. Geographically, the majority of revenue is from The United Kingdom.

Oxford BioDynamics (Oxford BioDynamics) Headlines

From GuruFocus

Bupa UK to cover EpiSwitch� CiRT for customers with cancer

By Business Wire • 10-18-2023

Oxford BioDynamics in San Francisco for the 41st Annual J.P. Morgan Healthcare Conference

By Business Wire Business Wire • 12-19-2022

Oxford Biodynamics Announces US Launch of its 94% Accurate EpiSwitch� Prostate Screening Blood Test to Men With Prostate Cancer Risk

By Business Wire • 09-26-2023

Oxford BioDynamics' Prostate Screening EpiSwitch� Blood Test Significantly Enhances Overall Detection Accuracy For At Risk Men

By Business Wire Business Wire • 02-06-2023

Oxford BioDynamics's Checkpoint Inhibitor Response Test (EpiSwitch� CiRT) Now Available in the UK

By Business Wire Business Wire • 06-21-2022

Oxford BioDynamics Receives Reimbursement Code for EpiSwitch� Prostate Screening (PSE) Test

By Business Wire • 10-03-2023

Oxford BioDynamics Joins ALS Biomarker Study Sponsored By Mitsubishi Tanabe Pharma America

By PRNewswire PRNewswire • 05-03-2019

Massachusetts General Hospital Reports Results of Interim Analysis from REFINE-ALS Biomarker Trial by Mitsubishi Tanabe Pharma USA, Utilizing Oxford Biodynamics' EpiSwitch� Platform for Prognostic Stratification of Fast Progression ALS

By Business Wire Business Wire • 12-16-2022

Oxford BioDynamics' EpiSwitch™ Featured in Presentations on Development and Validation of Blood-Based Predictive Biomarkers in Immune Checkpoint Inhibitor Programs

By PRNewswire PRNewswire • 11-09-2019

Oxford BioDynamics Advances EpiSwitch� Disease Severity Program for COVID-19 with Top US Academic Health Center, Oregon Health & Science University

By Business Wire Business Wire • 10-28-2020